<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MACROBID- nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule </strong><br>Procter and Gamble Pharmaceuticals, Inc.<br></p></div>
<h1>Macrobid<span class="Sup">®</span><br>(nitrofurantoin monohydrate/macrocrystals)<br>Capsules</h1>
<div class="Contents">
<div class="Section">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-2"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of <span class="Bold">Macrobid</span> and other antibacterial drugs, <span class="Bold">Macrobid</span> should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Nitrofurantoin is an antibacterial agent specific for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.  The <span class="Bold">Macrobid</span><span class="Sup">®</span> brand of nitrofurantoin is a hard gelatin capsule shell containing the equivalent of 100 mg of nitrofurantoin in the form of 25 mg of nitrofurantoin macrocrystals and 75 mg of nitrofurantoin monohydrate.</p>
<p>The chemical name of nitrofurantoin macrocrystals is 1-[[[5-nitro-2-furanyl]methylene]amino]-2,4-imidazolidinedione.  The chemical structure is the following:</p>
<div class="Figure">
<a name="f1"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1971e893-5fdb-41e3-a1e9-5e52deed03d1&amp;name=macrobid-01.jpg">
</div>
<p>The chemical name of nitrofurantoin monohydrate is 1-[[[5-nitro-2-furanyl]methylene]amino]-2,4- imidazolidinedione monohydrate.  The chemical structure is the following:</p>
<div class="Figure">
<a name="f2"></a><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1971e893-5fdb-41e3-a1e9-5e52deed03d1&amp;name=macrobid-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Inactive Ingredients:</span>  Each capsule contains carbomer 934P, corn starch, compressible sugar, D&amp;C Yellow No. 10, edible gray ink, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, lactose, magnesium stearate, povidone, talc, and titanium dioxide.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Each <span class="Bold">Macrobid</span> capsule contains two forms of nitrofurantoin.  Twenty-five percent is macrocrystalline nitrofurantoin, which has slower dissolution and absorption than nitrofurantoin monohydrate.  The remaining 75% is nitrofurantoin monohydrate contained in a powder blend which, upon exposure to gastric and intestinal fluids, forms a gel matrix that releases nitrofurantoin over time.  Based on urinary pharmacokinetic data, the extent and rate of urinary excretion of nitrofurantoin from the 100 mg <span class="Bold">Macrobid</span> capsule are similar to those of the 50 mg or 100 mg <span class="Bold">Macrodantin</span><span class="Sup">®</span> (nitrofurantoin macrocrystals) capsule.  Approximately 20-25% of a single dose of nitrofurantoin is recovered from the urine unchanged over 24 hours.</p>
<p>Plasma nitrofurantoin concentrations after a single oral dose of the 100 mg <span class="Bold">Macrobid</span> capsule are low, with peak levels usually less than 1 mcg/mL.  Nitrofurantoin is highly soluble in urine, to which it may impart a brown color.  When <span class="Bold">Macrobid</span> is administered with food, the bioavailability of nitrofurantoin is increased by approximately 40%.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-4.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span>  Nitrofurantoin is bactericidal in urine at therapeutic doses.  The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials.  Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules.  As a result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited.  The broad-based nature of this mode of action may explain the lack of acquired <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span> to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria.  Development of resistance to nitrofurantoin has not been a significant problem since its introduction in 1953.  Cross-resistance with antibiotics and sulfonamides has not been observed, and transferable resistance is, at most, a very rare phenomenon.</p>
<p>Nitrofurantoin, in the form of <span class="Bold">Macrobid</span>, has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following bacteria both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:  (See <span class="Bold"><a href="#s9">INDICATIONS AND USAGE</a></span>.)</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Gram-Positive Aerobes</span></dd>
<dt> </dt>
<dd><span class="Italics">         Staphylococcus saprophyticus</span></dd>
<dt> </dt>
<dd><span class="Bold">Gram-Negative Aerobes</span></dd>
<dt> </dt>
<dd><span class="Italics">         Escherichia coli</span></dd>
</dl>
<p>Nitrofurantoin also demonstrates <span class="Italics">in vitro</span> activity against the following microorganisms, although the clinical significance of these data with respect to treatment with <span class="Bold">Macrobid</span> is unknown:</p>
<dl>
<dt> </dt>
<dd><span class="Bold">Gram-Positive Aerobes</span></dd>
<dt> </dt>
<dd>         Coagulase-negative staphylococci</dd>
<dt> </dt>
<dd>         (including <span class="Italics">Staphylococcus epidermidis</span>)</dd>
<dt> </dt>
<dd><span class="Italics">         Enterococcus faecalis</span></dd>
<dt> </dt>
<dd><span class="Italics">         Staphylococcus aureus</span></dd>
<dt> </dt>
<dd><span class="Italics">         Streptococcus agalactiae</span></dd>
<dt> </dt>
<dd>         Group D streptococci</dd>
<dt> </dt>
<dd>         Viridans group streptococci</dd>
<dt> </dt>
<dd><span class="Bold"><br>Gram-Negative Aerobes</span></dd>
<dt> </dt>
<dd><span class="Italics">         Citrobacter amalonaticus</span></dd>
<dt> </dt>
<dd><span class="Italics">         Citrobacter diversus</span></dd>
<dt> </dt>
<dd><span class="Italics">         Citrobacter freundii</span></dd>
<dt> </dt>
<dd><span class="Italics">         Klebsiella oxytoca</span></dd>
<dt> </dt>
<dd><span class="Italics">         Klebsiella ozaenae</span></dd>
</dl>
<p>Nitrofurantoin is not active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Proteus</span> species or <span class="Italics">Serratia</span> species.  It has no activity against <span class="Italics">Pseudomonas</span> species.</p>
<p>Antagonism has been demonstrated <span class="Italics">in vitro</span> between nitrofurantoin and quinolone antimicrobials.  The clinical significance of this finding is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.2"></a><p></p>
<h2>Susceptibility Tests:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.2.1"></a><p></p>
<h3>Dilution techniques:</h3>
<p class="First">Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIC's).  These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MIC's should be determined using a standardized procedure.  Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of nitrofurantoin powder.  The MIC values should be interpreted according to the following criteria:</p>
<table width="100%">
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">MIC (μg/mL)</span></td>
<td align="left" valign="top"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center" valign="top">≤ 32</td>
<td align="left" valign="top">Susceptible  (S)</td>
</tr>
<tr>
<td align="center" valign="top">64</td>
<td align="left" valign="top">Intermediate  (I)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">≥ 128</td>
<td align="left" valign="top">Resistant      (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable.  A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.  A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the urine reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard nitrofurantoin powder should provide the following MIC values:</p>
<table width="100%">
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">Microorganism</span></td>
<td align="left" valign="top"><span class="Underline">MIC (μg/mL)</span></td>
</tr>
<tr>
<td align="center" valign="top">
<span class="Italics">       E. coli</span> ATCC 25922</td>
<td align="left" valign="top">     4-16</td>
</tr>
<tr>
<td align="center" valign="top">
<span class="Italics">           S. aureus</span> ATCC 29213</td>
<td align="left" valign="top">     8-32</td>
</tr>
<tr class="Last">
<td align="center" valign="top">
<span class="Italics">            E. faecalis</span> ATCC 29212</td>
<td align="left" valign="top">     4-16</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-4.2.2"></a><p></p>
<h3>Diffusion techniques:</h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.  One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 300 μg nitrofurantoin to test the susceptibility of microorganisms to nitrofurantoin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 300-μg nitrofurantoin disk should be interpreted according to the following criteria:</p>
<table width="100%">
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">Zone Diameter (mm)</span></td>
<td align="left" valign="top"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center" valign="top">≥ 17</td>
<td align="left" valign="top">Susceptible  (S)</td>
</tr>
<tr>
<td align="center" valign="top">15-16</td>
<td align="left" valign="top">Intermediate  (I)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">≤ 14</td>
<td align="left" valign="top">Resistant      (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.  Interpretation involves correlation of the diameter obtained in the disk test with the MIC for nitrofurantoin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.  For the diffusion technique, the 300 μg nitrofurantoin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table width="100%">
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Underline">Microorganism</span></td>
<td align="left" valign="top"><span class="Underline">Zone Diameter (mm)</span></td>
</tr>
<tr>
<td align="center" valign="top">
<span class="Italics">       E. coli</span> ATCC 25922</td>
<td align="left" valign="top">          20-25</td>
</tr>
<tr class="Last">
<td align="center" valign="top">
<span class="Italics">           S. aureus</span> ATCC 25923</td>
<td align="left" valign="top">          18-22</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First"><span class="Bold">Macrobid</span> is indicated only for the treatment of acute uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (acute <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli</span> or <span class="Italics">Staphylococcus saprophyticus.</span></p>
<p>Nitrofurantoin is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> or perinephric <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of <span class="Bold">Macrobid</span> and other antibacterial drugs, <span class="Bold">Macrobid</span> should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.  Consequently, many patients who are treated with <span class="Bold">Macrobid</span> are predisposed to persistence or reappearance of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span>.  (See <span class="Bold"><a href="#s38">CLINICAL STUDIES</a></span>.)  Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy.  If persistence or reappearance of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span> occurs after treatment with <span class="Bold">Macrobid</span>, other therapeutic agents with broader tissue distribution should be selected.  In considering the use of <span class="Bold">Macrobid</span>, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications.  Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug.</p>
<p>Because of the possibility of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent.  For the same reason, the drug is contraindicated in neonates under one month of age.</p>
<p><span class="Bold">Macrobid</span> is contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with nitrofurantoin.</p>
<p><span class="Bold">Macrobid</span> is also contraindicated in those patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nitrofurantoin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>WARNINGS:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="a11"></a><a name="section-7.1"></a><p></p>
<h2>Pulmonary reactions:</h2>
<p class="First"><span class="Bold">ACUTE, SUBACUTE, OR CHRONIC PULMONARY REACTIONS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH NITROFURANTOIN.  IF THESE REACTIONS OCCUR, MACROBID SHOULD BE DISCONTINUED AND APPROPRIATE MEASURES TAKEN.  REPORTS HAVE CITED PULMONARY REACTIONS AS A CONTRIBUTING CAUSE OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</span></p>
<p><span class="Bold">CHRONIC PULMONARY REACTIONS (DIFFUSE <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">INTERSTITIAL PNEUMONITIS</span> OR <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">PULMONARY FIBROSIS</span>, OR BOTH) CAN DEVELOP INSIDIOUSLY.  THESE REACTIONS OCCUR RARELY AND GENERALLY IN PATIENTS RECEIVING THERAPY FOR SIX MONTHS OR LONGER.  CLOSE MONITORING OF THE PULMONARY CONDITION OF PATIENTS RECEIVING LONG-TERM THERAPY IS WARRANTED AND REQUIRES THAT THE BENEFITS OF THERAPY BE WEIGHED AGAINST  POTENTIAL RISKS.  (SEE <a href="#s28">RESPIRATORY REACTIONS.</a>)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b11"></a><a name="section-7.2"></a><p></p>
<h2>Hepatotoxicity:</h2>
<p class="First">Hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, occur rarely.  Fatalities have been reported.  The onset of <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span> may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.  If <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occurs, the drug should be withdrawn immediately and appropriate measures should be taken.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c11"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which may become severe or irreversible, has occurred.  Fatalities have been reported.  Conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="437246" conceptname="Vitamin B deficiency">vitamin B deficiency</span>, and debilitating disease may enhance the occurrence of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.  Patients receiving long-term therapy should be monitored periodically for changes in renal function.</p>
<p><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span> has been reported rarely in postmarketing experience with nitrofurantoin formulations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d11"></a><a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>:</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> of the primaquine-sensitivity type have been induced by nitrofurantoin.  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients.  This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin.  <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> is an indication for discontinuing <span class="Bold">Macrobid</span>; <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> ceases when the drug is withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e11"></a><a name="section-7.5"></a><p></p>
<h2>Clostridium difficile-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>:</h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including nitrofurantoin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s12"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="s13"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span>  Patients should be advised to take <span class="Bold">Macrobid</span> with food (ideally breakfast and dinner) to further enhance tolerance and improve drug absorption.  Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy.</p>
<p>Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking <span class="Bold">Macrobid.</span></p>
<p>Patients should be counseled that antibacterial drugs including <span class="Bold">Macrobid</span> should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When <span class="Bold">Macrobid</span> is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by <span class="Bold">Macrobid</span> or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="s14"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">General:</span>  Prescribing <span class="Bold">Macrobid</span> in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s15"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span>  Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.  The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.</p>
<p>Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.  The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s16"></a><a name="section-8.4"></a><p></p>
<p class="First"><span class="Bold">Drug/Laboratory Test Interactions:</span>  As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur.  This has been observed with Benedict's and Fehling's solutions but not with the glucose enzymatic test.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s17"></a><a name="section-8.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span>  Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks.  Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF<span class="Sub">1</span> mice revealed no evidence of carcinogenicity.</p>
<p>Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F<span class="Sub">1</span> mice as shown by increased incidences of tubular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, benign mixed tumors, and granulosa cell tumors of the ovary.  In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcomas</span> of the bone, and neoplasms of the subcutaneous tissue.  In one study involving subcutaneous administration of 75 mg/kg nitrofurantoin to pregnant female mice, lung papillary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of unknown significance were observed in the F1 generation.</p>
<p>Nitrofurantoin has been shown to induce point mutations in certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and forward mutations in L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells.  Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture.  Results of the sex-linked recessive lethal assay in Drosophila were negative after administration of nitrofurantoin by feeding or by injection.  Nitrofurantoin did not induce heritable mutation in the rodent models examined.</p>
<p>The significance of the carcinogenicity and mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown.</p>
<p>The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug.  Doses of 10 mg/kg/day or greater in healthy human males may, in certain unpredictable instances, produce a slight to moderate spermatogenic arrest with a decrease in sperm count.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s18"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s19"></a><a name="section-8.6.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic effects:</span>  Pregnancy Category B.  Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin.  In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and a low incidence of minor and common malformations were observed.  However, at 25 times the human dose, <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> were not observed; the relevance of these findings to humans is uncertain.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s20"></a><a name="section-8.6.2"></a><p></p>
<p class="First"><span class="Bold">Non-teratogenic effects:</span>  Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in the F1 generation mice at doses 19 times the human dose on a mg/kg basis.  The relationship of this finding to potential human carcinogenesis is presently unknown.  Because of the uncertainty regarding the human implications of these animal data, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s21"></a><a name="section-8.7"></a><p></p>
<p class="First"><span class="Bold">Labor and Delivery:</span> See <span class="Bold"><a href="#s10">CONTRAINDICATIONS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s22"></a><a name="section-8.8"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span>  Nitrofurantoin has been detected in human breast milk in trace amounts.  Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  (See <span class="Bold"><a href="#s10">CONTRAINDICATIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s23"></a><a name="section-8.9"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:  Macrobid</span> is contraindicated in infants below the age of one month.  (See <span class="Bold"><a href="#s10">CONTRAINDICATIONS</a></span>.)  Safety and effectiveness in pediatric patients below the age of twelve years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s24"></a><a name="section-8.10"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span>  Clinical studies of <span class="Bold">Macrobid</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  Spontaneous reports suggest a higher proportion of pulmonary reactions, including fatalities, in elderly patients; these differences appear to be related to the higher proportion of elderly patients receiving long-term nitrofurantoin therapy.  As in younger patients, chronic pulmonary reactions generally are observed in patients receiving therapy for six months or longer (see <span class="Bold"><a href="#s11">WARNINGS</a></span>).  Spontaneous reports also suggest an increased proportion of severe hepatic reactions, including fatalities, in elderly patients (see <span class="Bold"><a href="#s11">WARNINGS</a></span>).</p>
<p>In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing <span class="Bold">Macrobid</span>.  This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications (see <span class="Bold"><a href="#s10">CONTRAINDICATIONS</a></span>).  Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s25"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">In clinical trials of <span class="Bold">Macrobid</span>, the most frequent clinical adverse events that were reported as possibly or probably drug-related were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (8%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6%), and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (1.5%).  Additional clinical adverse events reported as possibly or probably drug-related occurred in less than 1% of patients studied and are listed below within each body system in order of decreasing frequency:</p>
<p><span class="Bold">Gastrointestinal:</span>  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span></p>
<p><span class="Bold">Neurologic</span>:  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span></p>
<p><span class="Bold">Respiratory:</span>  Acute pulmonary <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (see <span class="Bold"><a href="#s11">WARNINGS</a></span>)</p>
<p><span class="Bold">Allergic:</span>  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">Dermatologic:</span>  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p>
<p><span class="Bold">Miscellaneous:</span>  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p>The following additional clinical adverse events have been reported with the use of nitrofurantoin:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal:</span>  <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">Sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.  There have been sporadic reports of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> with the use of nitrofurantoin.  The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antimicrobial treatment.  (See <span class="Bold"><a href="#s11">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Neurologic:</span>  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which may become severe or irreversible, has occurred.  Fatalities have been reported.  Conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="437246" conceptname="Vitamin B deficiency">vitamin B deficiency</span>, and debilitating diseases may increase the possibility of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. (See <span class="Bold"><a href="#s11">WARNINGS</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, and <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span> also have been reported with the use of nitrofurantoin.</p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign intracranial hypertension</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> have been reported rarely.  Bulging fontanels, as a sign of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in infants, have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-9.3"></a><p></p>
<h2>Respiratory:</h2>
<p class="First"><span class="Bold">CHRONIC, SUBACUTE, OR ACUTE PULMONARY <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY OCCUR WITH THE USE OF NITROFURANTOIN.</span></p>
<p><span class="Bold">CHRONIC PULMONARY REACTIONS GENERALLY OCCUR IN PATIENTS WHO HAVE RECEIVED CONTINUOUS TREATMENT FOR SIX MONTHS OR LONGER.  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">MALAISE</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">DYSPNEA</span> ON EXERTION, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">COUGH</span>, AND ALTERED PULMONARY FUNCTION ARE COMMON MANIFESTATIONS WHICH CAN OCCUR INSIDIOUSLY.  RADIOLOGIC AND HISTOLOGIC FINDINGS OF DIFFUSE <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">INTERSTITIAL PNEUMONITIS</span> OR <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">FIBROSIS</span>, OR BOTH, ARE ALSO COMMON MANIFESTATIONS OF THE CHRONIC PULMONARY REACTION.  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">FEVER</span> IS RARELY PROMINENT.</span></p>
<p><span class="Bold">THE SEVERITY OF CHRONIC PULMONARY REACTIONS AND THEIR DEGREE OF RESOLUTION APPEAR TO BE RELATED TO THE DURATION OF THERAPY AFTER THE FIRST CLINICAL SIGNS APPEAR.  PULMONARY FUNCTION MAY BE IMPAIRED PERMANENTLY, EVEN AFTER CESSATION OF THERAPY.  THE RISK IS GREATER WHEN CHRONIC PULMONARY REACTIONS ARE NOT RECOGNIZED EARLY.</span></p>
<p>In subacute pulmonary reactions, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> occur less often than in the acute form. Upon cessation of therapy, recovery may require several months.  If the symptoms are not recognized as being drug-related and nitrofurantoin therapy is not stopped, the symptoms may become more severe.</p>
<p>Acute pulmonary reactions are commonly manifested by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltration with consolidation or <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> on x-ray, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.  Acute reactions usually occur within the first week of treatment and are reversible with cessation of therapy.  Resolution often is dramatic.  (See <span class="Bold"><a href="#s11">WARNINGS</a></span>.)</p>
<p>Changes in EKG (e.g., non-specific ST/T wave changes, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>) have been reported in  association with pulmonary reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-9.4"></a><p></p>
<p class="First"><span class="Bold">Hepatic:</span> Hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, occur rarely.  (See <span class="Bold"><a href="#s11">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-9.5"></a><p></p>
<p class="First"><span class="Bold">Allergic:</span>  Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin has been reported.  Also, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; maculopapular, erythematous, or eczematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>; <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>; and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> have been reported.  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> represent the most frequent spontaneously-reported adverse events in worldwide postmarketing experience with nitrofurantoin formulations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-9.6"></a><p></p>
<p class="First"><span class="Bold">Dermatologic:</span>  <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-9.7"></a><p></p>
<p class="First"><span class="Bold">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span> secondary to <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-9.8"></a><p></p>
<p class="First"><span class="Bold">Miscellaneous:</span>  As with other antimicrobial agents, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> caused by resistant organisms, e.g., <span class="Italics">Pseudomonas</span> species or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species, can occur.</p>
<p>In clinical trials of <span class="Bold">Macrobid</span>, the most frequent laboratory adverse events (1-5%), without regard to drug relationship, were as follows: <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, increased AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), increased ALT (SGPT), <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, increased serum phosphorus.  The following laboratory adverse events also have been reported with the use of nitrofurantoin: glucose-6-phosphate dehydrogenase <span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span> (see <span class="Bold"><a href="#s11">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>.  In most cases, these hematologic abnormalities resolved following cessation of therapy. <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span> has been reported rarely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s34"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Occasional incidents of acute overdosage of nitrofurantoin have not resulted in any specific symptoms other than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is recommended.  There is no specific antidote, but a high fluid intake should be maintained to promote urinary excretion of the drug.  Nitrofurantoin is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s35"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First"><span class="Bold">Macrobid</span> capsules should be taken with food.</p>
<p><span class="Bold">Adults and Pediatric Patients Over 12 Years:</span>  One 100 mg capsule every 12 hours for seven days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s36"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First"><span class="Bold">Macrobid</span> is available as 100 mg opaque black and yellow capsules imprinted “Macrobid? on one half and “Norwich Eaton? on the other.</p>
<p><span class="Bold">NDC</span> 0149-0710-01     bottle of 100</p>
<p><span class="Bold">Store at controlled room temperature (59° to 86°F or 15° to 30°C).</span></p>
<p>Meets USP Dissolution Test 2</p>
<p>Rx Only</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s37"></a><a name="section-13"></a><p></p>
<h1>REFERENCES:</h1>
<ol class="Arabic">
<li>National Committee for Clinical Laboratory Standards.  Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 5th Edition.  Approved Standard NCCLS Document M7-A5.  NCCLS: Wayne, PA; 2003.</li>
<li>National Committee for Clinical Laboratory Standards.  Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard – 8th Edition.  Approved Standard NCCLS Document M2-A7. NCCLS: Wayne, PA; 2003.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s38"></a><a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES:</h1>
<p class="First">Controlled clinical trials comparing <span class="Bold">Macrobid</span> 100 mg p.o. q12h and <span class="Bold">Macrodantin</span> 50 mg p.o. q6h in the treatment of acute uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> demonstrated approximately 75% microbiologic eradication of susceptible pathogens in each treatment group.</p>
<p>Mfg. By: Norwich Pharmaceuticals, Inc.<br>North Norwich, NY 13814<br>Dist. by:  <span class="Bold">Procter &amp; Gamble Pharmaceuticals, Inc.,<br></span>TM Owner, Cincinnati, OH 45202<br></p>
<p>REVISED January 2009</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MACROBID 		
					</strong><br><span class="contentTableReg">nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0149-0710</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nitrofurantoin monohydrate</strong> (nitrofurantoin) </td>
<td class="formItem"></td>
<td class="formItem">75 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>nitrofurantoin, macrocrystalline</strong> (nitrofurantoin) </td>
<td class="formItem"></td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carbomer 934P</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>corn starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>compressible sugar</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edible gray ink</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">black (BLACK) , yellow (YELLOW) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Macrobid;Norwich;Eaton</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0149-0710-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Procter and Gamble Pharmaceuticals, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>B277C368-5E66-F180-2675-55CC49711E59</div>
<div>Set id: 1971e893-5fdb-41e3-a1e9-5e52deed03d1</div>
<div>Version: 5</div>
<div>Effective Time: 20090323</div>
</div>
</div> <div class="DistributorName">Procter and Gamble Pharmaceuticals, Inc.</div></p>
</body></html>
